New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
06:03 EDTAMSGAmSurg to acquire Sheridan Healthcare for $2.35B
AMSURG and Sheridan Healthcare, a portfolio company of Hellman & Friedman, announced that their respective boards have unanimously approved a definitive agreement under which AMSURG will acquire Sheridan Healthcare in a cash and stock transaction valued at approximately $2.35B. The transaction, which is subject to customary closing conditions and regulatory approvals, is expected to close in the third quarter. The combined company will have a total addressable market of approximately $70B and will encompass more than 4,600 physician relationships across 38 states. The transaction is valued at $2.35B and will be funded via fully committed financing from Citi and the expected issuance to Sheridan’s equity holders of AMSURG equity currently valued at approximately $615M. The transaction is expected to close in the third quarter and is subject to, among other things, the expiration or termination of the applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, as well as other customary closing conditions. Citi is serving as financial advisor to AMSURG and Bass, Berry & Sims PLC is providing legal counsel. Barclays, Credit Suisse and Goldman, Sachs & Co. are serving as financial advisors to Sheridan and Simpson Thacher & Bartlett LLP is providing legal counsel.
News For AMSG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 25, 2015
09:29 EDTAMSGAmSurg added to Conviction List at Avondale
Avondale added AmSurg to the Conviction List given solid execution and continued growth potential. The firm maintains its Outperform rating and raised its price target to $94 from $90 on shares.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use